Join us on 12-15-2022 for a live seminar about RNA SEQ
Originally invented and validated inside a major pharma company then further developed by Alloy, our foundational suite of highly immunocompetent transgenic mice is engineered to drive the greatest potential diversity of unique human antibodies binding to your target of interest, with broad epitopic coverage. The antibodies produced exhibit high affinity, requiring little-to-no optimization.
Our simple, royalty-free licensing process makes this foundational technology accessible to drug discovery teams of all sizes, with the know-how needed to achieve the best results.
Partners can access our expanding portfolio of transgenic strains designed to address a range of discovery challenges, with the additional option of bespoke strains custom-tailored to your project.
The platform exhibits healthy cellularity, human-like repertoire, and robust immune response upon immunization. Its proven, rich discovery output offers wide epitopic coverage and a diverse range of binding affinity—and has a track record of success in difficult targets.
The ATX-Gx humanized mice produce a robust immune response, with immune repertoires similar to wild-type (WT) animals and humans.
The ATX-Gx strain produced strong seroconversion levels by immunization with a recombinant protein target antigen.
The ATX-Gx generates binders with a diverse range of affinity against different target antigens.
The ATX-Gx has expanded into a suite of 10 strains to offer our discovery partners the right tools to solve distinct antibody discovery challenges. Connect with our team of experts to determine the right ATX-Gx strain to meet your therapeutic goals.
Get started with human antibody discovery in less than two weeks by licensing the ATX-Gx mice platform for use in your lab. Or, engage in a bespoke antibody discovery campaign with ATX-Gx platform experts through Alloy Antibody Discovery Services.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.